Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Bayer: FDA Oks Natazia As First Combined Oral Contraceptive To Treat HMB

Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK) said the U.S. Food and Drug Administration, or FDA, has approved a new indication for Natazia (estradiol valerate and dienogest) tablets for the treatment of heavy menstrual bleeding, or HMB, that is not caused by any diagnosed conditions of the uterus (womb), in women who choose to use a combined oral contraceptive for contraception.

The company noted that with the above approval, Natazia is the first and only combined oral contraceptive indicated for the treatment of heavy menstrual bleeding in the U.S.

Dr. Flemming Ornskov, Head of Strategic Marketing General Medicine at Bayer HealthCare Pharmaceuticals, said, "As the first combined oral contraceptive treatment for heavy menstrual bleeding, Natazia represents a non-invasive treatment approach for this medical condition in addition to our intrauterine system Mirena. Both products underline Bayer's ongoing commitment to advancing women's health by providing them with multiple treatment options."

Click here to receive FREE breaking news email alerts for Bayer AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
European stocks are seen opening lower on Monday, tracking weak commodity prices and a subdued trend across the Asia-Pacific region as investors look ahead to Chinese manufacturing data due on Tuesday for important clues about China's growth outlook. China is experiencing stable growth and there... Specialty drugmaker Horizon Pharma plc (HZNP) on Friday managed to redomicile itself as an entity incorporated in Ireland following the completion of its $660 million acquisition of Vidara Therapeutics International plc. The deal will help it avoid paying the high rate of U.S. corporate taxes. The... Stocks showed a lack of direction over the course of the trading day on Friday after failing to sustain an initial upward move. Despite the choppy trading, the Dow once again managed to end the session at a new record closing high. The major averages turned in a mixed performance on the day.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.